Clinical Trial Update: A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for GNC-038 injection in Phase 1/2 studies for relapsed or refractory NK/T-cell lymphoma and Non-Hodgkin lymphoma, with the trial currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Natural Killer T-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• GNC-038 Injection (GNC-038)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING